Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
复制标题
DOI：
10.1002/dad2.12492
复制
发表时间：
2023-10
影响因子：
5.3
通讯作者：
Alosco, Michael L
中科院分区：
文献类型：
--
作者：
Ally, Madeline;Sugarman, Michael A;Zetterberg, Henrik;Blennow, Kaj;Ashton, Nicholas J;Karikari, Thomas K;Aparicio, Hugo J;Frank, Brandon;Tripodis, Yorghos;Martin, Brett;Palmisano, Joseph N;Steinberg, Eric G;Simkin, Irene;Farrer, Lindsay A;Jun, Gyungah R;Turk, Katherine W;Budson, Andrew E;O'Connor, Maureen K;Au, Rhoda;Goldstein, Lee E;Kowall, Neil W;Killiany, Ronald;Stern, Robert A;Stein, Thor D;McKee, Ann C;Qiu, Wei Qiao;Mez, Jesse;Alosco, Michael L
本研究检查了血浆胶质纤维酸性蛋白 (GFAP) 作为阿尔茨海默氏病 (AD) 引起的认知障碍的生物标志物以及血浆神经丝轻链 (NfL) 和磷酸化 tau (p-tau)181+231 的作用。使用 Simoa 平台对跨越 AD 连续体的 567 名参与者的血浆样本进行了分析。对认知诊断、神经心理学测试和痴呆严重程度进行了横断面和纵向结果的检查。血浆 GFAP 将 AD 痴呆与正常认知（调整后的平均差 = 0.90 标准差 [SD]）和轻度认知障碍（调整后的平均差 = 0.72 SD）区分开来，并且与其他血浆生物标志物相比，表现出更好的辨别力。较高的 GFAP 与痴呆严重程度和 12 项神经心理学测试中的 11 项表现较差相关。从纵向来看，GFAP 预测记忆力下降，但没有预测转化为轻度认知障碍或痴呆。血浆 GFAP 与疑似 AD 相关的临床结果相关，并且可能有助于血浆生物标志物组检测体内 AD。
This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231. Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross‐sectional and longitudinal outcomes. Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia. Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD.